Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial

NCT05712694 is registered in ClinicalTrials.gov with Polaris Group as lead sponsor.

NCT NCT05712694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05712694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial
Lead sponsor
Polaris Group
Phase
Phase 3
Overall status
Terminated
Start date
November 29, 2023
Completion date
May 25, 2026
Enrollment
218 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma